[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vexus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vexus":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,55,81,111,139,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100619553","fluid-balance-guided-by-modified-venous-excess-ultrasonography-versus-standard-care-in-patients-with-acute-kidney-injury-receiving-continuous-renal-replacement-therapy-100619553",false,"NCT07346118","Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy","Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: A Multicentre Randomised Controlled Trial","mVExUS-CRRT","Inclusion Criteria:\n\n* Adults (≥ 18 years of age)\n* Admitted to ICU\n* Acute kidney injury by KDIGO criteria\n* Initiated CRRT by at least one of the following indications for RRT initiation:\n* Serum potassium ≥ 6.0 mmol\u002FL, or\n* pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol\u002FL, or\n* Evidence of severe respiratory failure, based on a PaO2\u002FFiO2 ≤ 200 and clinical perception of volume overload, or\n* Persistent severe AKI (sCr remains \\> 50% the value recorded at randomization) for \\> 72 hours from randomization\n* Participants giving informed consent\n\nExclusion Criteria:\n\n* Refuse to participate\n* Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy\n* Kidney transplant recipient\n* Receive RRT before ICU admission within 90 days\n* Structural kidney diseases which will interfere with intrarenal doppler ultrasound e.g. renal artery stenosis, autosomal dominant polycystic kidney disease\n* Patients with previously known conditions that interfere with portal doppler assessment, namely liver cirrhosis, severe tricuspid regurgitation with structural heart disease or massive ascites.\n* Underlying disease process with a life expectancy less than 90 days\n* Pregnancy\n* Severe cardiac rhythm disturbances (tachyarrhythmia, supraventricular tachycardia)\n* Intra-cardiac shunts; Ventricle septal defect, patent foramen ovale, atrial septal defect\n* Aortic aneurysm\n* Intra-abdominal hypertension (intraabdominal pressure ≥20 mmHg)\n* Expected life expectancy \\\u003C48 hours\n* Receiving extracorporeal membrane oxygenation (ECMO)","ALL","18 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this randomised controlled trial is to compare the cumulative fluid balance over the first 72 h following inclusion guided by mVExUS versus standard of care in critically ill patients with acute kidney injury receiving CRKT . It will also compare the proportion of CRRT-related complications-including intradialytic hypotension and arrhythmias-between patients managed with mVExUS-guided fluid management and those receiving standard care.\n\nThe main questions it aims to answer are:\n\nDoes fluid removal rate guided by mVExUS will reduce cumulative fluid balance over the course of the first 72 h of CRRT in ICU patients compared to standard care\n\nParticipants will:\n\nGet fluid assessment by mVExUS protocol or a strandard care every 8 hours for 72 hours",[27,28,29,30,31,32,33],"AKI - Acute Kidney Injury","Fluid Balance","Acute Circulatory Failure","Continuous Renal Replacement Therapy (CRRT)","VExUS","Passive Leg Raising","Biomarkers \u002F Blood",[35,36,37,38,39,40,41,42],"Acute kidney injury","Fluid balance","Acute circulatory failure","Continuous kidney replacement therapy","mVExUS","Modified Venous Excess Ultrasound","Passive leg raising","Biomarker","NOT_YET_RECRUITING","2026-05-05",{"date":46,"type":47},"2026-05-07","ACTUAL",{"date":49,"type":21},"2026-07-01",{"date":51,"type":21},"2029-05-01",{"name":53,"class":54},"Chulalongkorn University","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100615374","doppler-evaluation-for-congestive-acute-kidney-injury-in-critical-illness-100615374","NCT07291778","Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness","The Impact of VeXUS-guided Fluid Management in ICU Populations on Renal Function","DECONGEST-AKI","Inclusion Criteria:\n\n* Adults (≥18 years old)\n* Admitted to the MICU, MCCU, or CCU within 24 hours of admission\n* Acute kidney injury (AKI) (based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria)\n* Adequate acoustic windows for a complete VExUS scan\n\nExclusion Criteria:\n\n* \\\u003C 18 years old\n* pregnant women\n* End-stage renal disease (ESRD) or prior renal transplant\n* Acute tubular necrosis (ATN) defined by urinalysis (≥2+ protein, ≥2+ blood, ≥1 muddy brown cast, ≥1 RBC cast, or ≥1 dysmorphic RBC)'\n* Prior Whipple procedures\n* currently incarcerated",{"count":64,"type":21},100,[24],"This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.",[68,31],"Acute Kidney Injury",[31,70,68,71],"Fluid Management","ICU","2026-04-30",{"date":74,"type":47},"2026-05-06",{"date":49,"type":21},{"date":77,"type":21},"2027-07-01",{"name":79,"class":54},"University of Alabama at Birmingham",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100635908","vexus-assessment-and-natriuresis-guided-diuretic-therapy-in-acute-heart-failure-100635908","NCT07558798","Vexus Assessment and Natriuresis-guided Diuretic Therapy in Acute Heart Failure","VANTAGE-HF","Inclusion Criteria:\n\n* Age \\>18 years\n* Hospitalization with AHF, either de novo or worsening of chronic HF\n* Able to provide written informed consent\n* Requirement of intravenous loop diuretic treatment as judged by the treating physician\n\nExclusion Criteria:\n\n* Dyspnea primarily due to non-cardiac causes\n* Advanced renal disease or estimated glomerular filtration rate (eGFR) \\\u003C 20 mL\u002Fmin\u002F1.73m2 at screening or on-going dialysis.\n* Enrollment in another study interfering with the treatment algorithm of the current study\n* Inability to follow the treatment protocol\n* Language barriers requiring the need for an external interpreter\n* Pregnant or nursing (lactating) women\n* Very short life expectancy (\\\u003C30 days)",{"count":89,"type":21},270,[24],"This study evaluates whether natriuresis-guided diuretic therapy improves outcomes in patients with acute heart failure (AHF) and severe congestion. All patients hospitalized with AHF will be screened using Venous Excess Ultrasound (VExUS) and randomized 1:1 to either natriuresis-guided escalation of loop diuretics or standard care. The primary endpoint, evaluated in patients with VExUS grade 3 (severe congestion), is a hierarchical composite (win ratio) of 90-day mortality, 90-day rehospitalization, and hospital length of stay. Key secondary endpoints (hierarchical) include (1) difference in win ratio between patients with VExUS 3 versus VExUS 0-2 at hospital admission (assessed by interaction testing and statistically tested only if the primary endpoint is significant) and (2) win ratio (primary endpoint) tested among patients with VExUS 0-2 at hospital admission (statistically tested only if the first key seconday endpoint is significant). Exploratory endpoints include in-hospital clinical, hemodynamic, and biochemical outcomes (mortality, eGFR, NT-proBNP, NYHA class, VExUS score, natriuresis\u002Fdiuresis, and patient-reported dyspnea), associations between congestion markers (VExUS, FibroScan, lung ultrasound, clinical score, and NT-proBNP), as well as quality of life at 90 days, GDMT optimization score at discharge, and long-term time to readmission and mortality assessed through registry linkage.",[93,94,31,95],"Venous Congestion","Heart Failure Acute","Diuretics",[97,98,99,100,101],"loop diuretics","heart failure","acute heart failure","vexus","congestion","2026-04-23",{"date":72,"type":47},{"date":105,"type":21},"2026-04",{"date":107,"type":21},"2028-06",{"name":109,"class":54},"University Hospital, Akershus",2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100619381","quantification-of-systemic-congestion-by-ultrasound-as-a-predictor-of-weaning-failure-from-mechanical-ventilation-100619381","NCT07343882","Quantification of Systemic Congestion by Ultrasound As a Predictor of Weaning Failure From Mechanical Ventilation","SCOUT","Inclusion Criteria:\n\n* Patients aged \\> 18 years.\n* Admitted to an Intensive Care Unit (ICU).\n* Requiring invasive mechanical ventilation for more than 48 hours.\n* Meeting the center's standard criteria to begin weaning and undergo an SBT.\n\nExclusion Criteria:\n\n* Inadequate ultrasound window for assessment.\n* Presence of \"do not reintubate\" orders.\n* Patients with a tracheostomy.\n* Presence of atrial fibrillation.\n* Diagnosed liver cirrhosis (portal hypertension).\n* Absence of qualified personnel to perform the ultrasound at the time of the SBT.\n* Denial of informed consent.",{"count":119,"type":21},350,[24],"Mechanical ventilation is an essential, life-saving therapy in the ICU, allowing critically ill patients to rest and recover. Transitioning patients back to spontaneous breathing-known as weaning-is clinically challenging. The first attempt, the Spontaneous Breathing Trial (SBT), fails in 10-30% of cases. Identifying the mechanisms behind failure is crucial, as unsuccessful weaning prolongs ICU stay and increases the risk of reintubation, which worsens prognosis. The SCOUT study aims to improve prediction and management of weaning failure.\n\nThe main objective of the study is to evaluate whether a specific ultrasound-based method, the Venous Excess Ultrasound Score (VExUS), can predict failure of weaning from mechanical ventilation. A key pathophysiological factor is systemic venous congestion. When a patient initiates an SBT, the increased respiratory effort shifts venous return and may precipitate cardiovascular decompensation with pulmonary fluid accumulation, termed weaning-induced pulmonary edema (WIPO). Notably, this may occur even in patients without known cardiac disease.\n\nDetecting clinically relevant congestion before SBT is difficult. Fluid balance and body weight are imprecise, physical examination lacks sensitivity, and biomarkers such as NT-proBNP have limited predictive capacity. VExUS offers a promising, non-invasive approach by directly assessing venous flow patterns in major veins (inferior vena cava, hepatic, portal, and renal veins), providing an estimation of systemic venous pressure and congestion. The central hypothesis is that elevated VExUS grades prior to SBT will identify patients at high risk of failure, enabling proactive optimization and potentially improving outcomes.\n\nSCOUT is designed as a prospective, multicenter, observational study. Standard clinical management of mechanical ventilation and weaning remains unchanged. After informed consent, baseline data will be obtained immediately before SBT, including vital signs, ventilator parameters, blood sampling, and three non-invasive ultrasound assessments: cardiac, pulmonary, and VExUS. During the 30-120-minute SBT, the patient breathes with reduced ventilatory support while their clinical tolerance is evaluated. At the end of the SBT, selected measurements are repeated. Weaning failure is defined as: early termination of SBT due to intolerance, need for invasive or non-invasive ventilation within 48 h after extubation, or death within 48 h. Data are anonymized and stored securely (REDCap) in compliance with Spanish and EU data protection regulations.\n\nThe study is low-risk and provides no direct individual benefit, but may benefit future ICU patients by improving weaning strategies and prognostication.",[123,124,125,126,31],"Weaning Failure","Pulmonary Edema - Acute","Mechanical Ventilation","POCUS",[128,129],"Weaning induced pulmonary edema","Venous Excess Ultrasound grading system","2026-01-16",{"date":132,"type":47},"2026-01-21",{"date":134,"type":21},"2026-04-01",{"date":136,"type":21},"2027-06-01",{"name":138,"class":54},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":146,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":80},"100612845","effect-of-vexus-ultrasound-protocol-venous-excess-ultrasound-on-perioperative-fluid-management-on-the-incidence-of-postoperative-pulmonary-complications-and-postoperative-acute-kidney-injury-in-patients-undergoing-thoracic-surgery-100612845","NCT07258875","Effect of VExUS Ultrasound Protocol (Venous Excess Ultrasound) on Perioperative Fluid Management, on the Incidence of Postoperative Pulmonary Complications and Postoperative Acute Kidney Injury in Patients Undergoing Thoracic Surgery","VEXUS","Inclusion Criteria:\n\n* Adults \\>18 years undergoing video assisted thoracic surgery\u002F lobectomy requiring one-lung ventilation.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Pneumonectomy.\n* Young athletes (risk of physiologically large IVC \\>2 cm).\n* Moderate-severe tricuspid regurgitation, moderate to severe pulmonary hypertension\n* Heart failure with reduced ejection fraction, EF\\\u003C35%\n* Portal hypertension, portal vein thrombosis, or liver cirrhosis.\n* Stage 4 or end-stage chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² or dialysis).\n* Transfusion with more than 2 packed red blood cells unit perioperatively (intraoperatively, in the PACU, in the ward)",true,{"count":148,"type":21},230,[24],"This study aims to investigate the effect of a VExUS ultrasound guided protocol of perioperative fluid management within a goal-directed therapy framework, on postoperative respiratory complications, and the occurrence of acute kidney injury (AKI) in patients undergoing thoracic surgery.",[152,31,70,68,153],"Thoracic Surgery With One-lung Ventilation","Postoperative Pulmonary Complications (PPCs)",[155],"VExUS, fluid management, pulmonary complications, acute kidney injury, thoracic surgery, one lung ventilation","RECRUITING","2025-11-20",{"date":159,"type":47},"2025-12-02",{"date":161,"type":47},"2024-11-27",{"date":163,"type":21},"2029-11-01",{"name":165,"class":54},"University of Crete",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100602532","prognostic-power-of-the-vexus-score-in-septic-shock-effectiveness-in-mortality-prediction-100602532","NCT07124741","Prognostic Power of the VEXUS Score in Septic Shock: Effectiveness in Mortality Prediction","Prognostic Power of the VEXUS Score in Septic Shock: Efficacy in Mortality Prediction","Inclusion Criteria:\n\n* Age\\>18\n* Patients monitored for septic shock in intensive care unit\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18\n* Severe obesity precluding adequate ultrasonographic imaging.\n* Patients in whom venous structures cannot be clearly assessed via ultrasonography due to anatomical or technical reasons (e.g., adhesions following abdominal surgery).\n* Patients receiving dialysis due to chronic kidney disease or initiating dialysis for acute kidney failure.\n* Chronic heart failure.\n* Patients with advanced valvular insufficiency or advanced pulmonary hypertension.\n* Patients with portal hypertension or advanced-stage liver cirrhosis.\n* Presence of acute or chronic thrombosis in the inferior vena cava or other venous structures within the scoring area.\n* Refusal to participate",{"count":64,"type":21},"OBSERVATIONAL","This study aims to evaluate the prognostic power of the VEXUS Score in predicting mortality among patients with septic shock in intensive care units.",[177,31],"Septic Shock","2025-08-14",{"date":180,"type":47},"2025-08-15",{"date":182,"type":21},"2026-03-30",{"date":184,"type":21},"2026-08",{"name":186,"class":187},"Antalya Training and Research Hospital","OTHER_GOV"]